AP2000001735A0 - Treatment of diabetes with thiazolidinedione insulin secretagogue and alpha glucocidase inhibitor. - Google Patents
Treatment of diabetes with thiazolidinedione insulin secretagogue and alpha glucocidase inhibitor.Info
- Publication number
- AP2000001735A0 AP2000001735A0 APAP/P/2000/001735A AP2000001735A AP2000001735A0 AP 2000001735 A0 AP2000001735 A0 AP 2000001735A0 AP 2000001735 A AP2000001735 A AP 2000001735A AP 2000001735 A0 AP2000001735 A0 AP 2000001735A0
- Authority
- AP
- ARIPO
- Prior art keywords
- treatment
- alpha
- diabetes
- glucocidase
- inhibitor
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 3
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 title 1
- 229940122199 Insulin secretagogue Drugs 0.000 title 1
- 229940123464 Thiazolidinedione Drugs 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 4
- 102000004877 Insulin Human genes 0.000 abstract 2
- 108090001061 Insulin Proteins 0.000 abstract 2
- 229940125396 insulin Drugs 0.000 abstract 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 abstract 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 231100000489 sensitizer Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, which method comprises administering an effective non-toxic and pharmacuetically acceptable amount of an insulin sensitiser, an insulin secretagogueand an alpha glucosidase inhibitor antihyperglycaemic agent, to amammal in need thereof; and composition for use in such method.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9715298A GB9715298D0 (en) | 1997-07-18 | 1997-07-18 | Novel method of treatment |
| PCT/GB1998/002112 WO1999003478A1 (en) | 1997-07-18 | 1998-07-16 | Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AP2000001735A0 true AP2000001735A0 (en) | 2000-01-16 |
Family
ID=10816170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/2000/001735A AP2000001735A0 (en) | 1997-07-18 | 2000-01-14 | Treatment of diabetes with thiazolidinedione insulin secretagogue and alpha glucocidase inhibitor. |
Country Status (27)
| Country | Link |
|---|---|
| EP (1) | EP1001784A1 (en) |
| JP (1) | JP2001510160A (en) |
| KR (1) | KR20010021952A (en) |
| CN (1) | CN1263467A (en) |
| AP (1) | AP2000001735A0 (en) |
| AR (2) | AR016350A1 (en) |
| AU (1) | AU8449098A (en) |
| BG (1) | BG104062A (en) |
| BR (1) | BR9810292A (en) |
| CA (1) | CA2297133A1 (en) |
| CO (1) | CO4940489A1 (en) |
| DZ (1) | DZ2563A1 (en) |
| EA (1) | EA200000140A1 (en) |
| GB (1) | GB9715298D0 (en) |
| HU (1) | HUP0003626A3 (en) |
| ID (1) | ID23804A (en) |
| IL (1) | IL133907A0 (en) |
| MA (1) | MA24608A1 (en) |
| NO (1) | NO20000230D0 (en) |
| OA (1) | OA11312A (en) |
| PE (1) | PE99499A1 (en) |
| PL (1) | PL338140A1 (en) |
| SK (1) | SK612000A3 (en) |
| TR (1) | TR200000133T2 (en) |
| UY (1) | UY25101A1 (en) |
| WO (1) | WO1999003478A1 (en) |
| ZA (1) | ZA986364B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| US7045519B2 (en) | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| DK1133312T3 (en) | 1999-06-21 | 2008-01-02 | Lilly Co Eli | Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof for the treatment of non-insulin-dependent diabetes |
| JP2003520226A (en) * | 2000-01-21 | 2003-07-02 | ノバルティス アクチエンゲゼルシャフト | Combination comprising a dipeptidyl peptidase-IV inhibitor and an antidiabetic agent |
| JP4917712B2 (en) * | 2000-02-24 | 2012-04-18 | 武田薬品工業株式会社 | Concomitant medication |
| EP1295609A4 (en) * | 2000-02-24 | 2004-11-03 | Takeda Chemical Industries Ltd | DRUGS CONTAINING COMBINED ACTIVE INGREDIENTS |
| BRPI0206432A2 (en) | 2001-01-12 | 2016-10-25 | Sun Pharmaceutical Ind Ltd | methods for administering two or more active therapeutic agents and for treating diabetes mellitus or symptoms associated with diabetes mellitus in a human and spaced drug release system |
| FR2832930A1 (en) * | 2001-12-03 | 2003-06-06 | Lipha | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-GLUCOSIDASE INHIBITOR AND A THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF FOR THE PREPARATION OF MEDICINES FOR TREATING DIABETES |
| CN1874774B (en) | 2003-10-31 | 2011-04-13 | 武田药品工业株式会社 | Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester |
| CN101103993B (en) * | 2006-07-14 | 2011-03-30 | 北京华安佛医药研究中心有限公司 | Hypoglycemic medicine composition |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993003724A1 (en) * | 1991-08-26 | 1993-03-04 | The Upjohn Company | Pharmaceutical composition containing 3-guanidinopropionic acid and pioglitazone glibenclamide or glimepiride |
| US5917052A (en) * | 1994-09-28 | 1999-06-29 | Shaman Pharmaceuticals, Inc. | Hypoglycemic agent from cryptolepis |
| TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
-
1997
- 1997-07-18 GB GB9715298A patent/GB9715298D0/en active Pending
-
1998
- 1998-07-15 DZ DZ980173A patent/DZ2563A1/en active
- 1998-07-16 KR KR1020007000517A patent/KR20010021952A/en not_active Withdrawn
- 1998-07-16 PE PE1998000630A patent/PE99499A1/en not_active Application Discontinuation
- 1998-07-16 PL PL98338140A patent/PL338140A1/en unknown
- 1998-07-16 TR TR2000/00133T patent/TR200000133T2/en unknown
- 1998-07-16 CA CA002297133A patent/CA2297133A1/en not_active Abandoned
- 1998-07-16 CN CN98807147A patent/CN1263467A/en active Pending
- 1998-07-16 IL IL13390798A patent/IL133907A0/en unknown
- 1998-07-16 SK SK61-2000A patent/SK612000A3/en unknown
- 1998-07-16 HU HU0003626A patent/HUP0003626A3/en unknown
- 1998-07-16 ID IDW20000077A patent/ID23804A/en unknown
- 1998-07-16 AR ARP980103482A patent/AR016350A1/en unknown
- 1998-07-16 MA MA25172A patent/MA24608A1/en unknown
- 1998-07-16 WO PCT/GB1998/002112 patent/WO1999003478A1/en not_active Ceased
- 1998-07-16 AU AU84490/98A patent/AU8449098A/en not_active Abandoned
- 1998-07-16 JP JP2000502777A patent/JP2001510160A/en active Pending
- 1998-07-16 EP EP98935129A patent/EP1001784A1/en not_active Withdrawn
- 1998-07-16 EA EA200000140A patent/EA200000140A1/en unknown
- 1998-07-16 BR BR9810292-3A patent/BR9810292A/en not_active IP Right Cessation
- 1998-07-17 CO CO98040749A patent/CO4940489A1/en unknown
- 1998-07-17 ZA ZA9806364A patent/ZA986364B/en unknown
- 1998-07-17 UY UY25101A patent/UY25101A1/en not_active Application Discontinuation
-
1999
- 1999-06-28 AR ARP990103110A patent/AR019724A2/en unknown
-
2000
- 2000-01-06 BG BG104062A patent/BG104062A/en unknown
- 2000-01-14 AP APAP/P/2000/001735A patent/AP2000001735A0/en unknown
- 2000-01-17 NO NO20000230A patent/NO20000230D0/en not_active Application Discontinuation
- 2000-01-18 OA OA1200000013A patent/OA11312A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO4940489A1 (en) | 2000-07-24 |
| NO20000230L (en) | 2000-01-17 |
| NO20000230D0 (en) | 2000-01-17 |
| PL338140A1 (en) | 2000-09-25 |
| IL133907A0 (en) | 2001-04-30 |
| PE99499A1 (en) | 1999-12-18 |
| BR9810292A (en) | 2000-09-19 |
| WO1999003478A1 (en) | 1999-01-28 |
| MA24608A1 (en) | 1999-04-01 |
| DZ2563A1 (en) | 2003-02-15 |
| BG104062A (en) | 2000-11-30 |
| TR200000133T2 (en) | 2000-09-21 |
| OA11312A (en) | 2003-10-24 |
| ID23804A (en) | 2000-05-11 |
| ZA986364B (en) | 2000-01-17 |
| GB9715298D0 (en) | 1997-09-24 |
| AU8449098A (en) | 1999-02-10 |
| AR016350A1 (en) | 2001-07-04 |
| SK612000A3 (en) | 2000-07-11 |
| HUP0003626A3 (en) | 2001-12-28 |
| CA2297133A1 (en) | 1999-01-28 |
| EP1001784A1 (en) | 2000-05-24 |
| AR019724A2 (en) | 2002-03-13 |
| UY25101A1 (en) | 2000-12-29 |
| CN1263467A (en) | 2000-08-16 |
| KR20010021952A (en) | 2001-03-15 |
| HUP0003626A2 (en) | 2001-05-28 |
| EA200000140A1 (en) | 2000-06-26 |
| JP2001510160A (en) | 2001-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA02012763A (en) | Combinations of depeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabete mellitus. | |
| MY155219A (en) | Treatment of diabetes with thiazolidinedione, insulin secretagogue and biguanide | |
| CA2294582A1 (en) | Treatment of diabetes with thiazolidinedione and metformin | |
| MY124695A (en) | Novel composition and use. | |
| AP2000001735A0 (en) | Treatment of diabetes with thiazolidinedione insulin secretagogue and alpha glucocidase inhibitor. | |
| TR199903095T2 (en) | Treatment of diabetes with rosiglitazone and insulin. | |
| AP9901720A0 (en) | Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitors. | |
| MY125855A (en) | Treatment of diabetes with a thiazolidinedione and sulphonylurea | |
| MY138246A (en) | Treatment of diabetes with thiazolidione and sulphonylurea. | |
| HK1041201A1 (en) | Compatibility of beta agonists and antidiabetic agents | |
| WO2001047509A3 (en) | Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions | |
| IL143088A0 (en) | A method for the treatment of type 2 diabetes mellitus and conditions associated therewith, and a pharmaceutical composition comprising an insulin sensitiser for use in such a method | |
| ECSP982591A (en) | NEW METHOD OF TREATMENT IV | |
| AP2000001787A0 (en) | Use of thiazolidinediones for the treatment of hyperglycaemia. | |
| ECSP982542A (en) | NEW METHOD OF TREATMENT III | |
| HUP0002668A2 (en) | Treatment of diabetes with thiazolidinedione and metformin | |
| ECSP982534A (en) | NEW METHOD OF TREATMENT | |
| ECSP982593A (en) | NEW METHOD OF TREATMENT VI | |
| AP1692A (en) | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent. | |
| ECSP982535A (en) | NEW TREATMENT METHOD (I) |